Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Webinar on Mimicking Perfusion Culture Using Micro Bioreactors

Published: Friday, February 14, 2014
Last Updated: Friday, February 14, 2014
Bookmark and Share
Presents validation data for improving media screening and process optimization.

TAP Biosystems has announced that it will be co-presenting a new bioprocess webinar with Irvine Scientific, a major producer of cell culture media, on Wednesday March 12th 2014 at 9 am PST / 12 noon EST / 4 pm GMT.

The live event will detail how to use ambr™ automated micro bioreactor system in alternative semi-continuous modes to mimic perfusion cultures and how this can be used to save time with process optimization and media screening.

Bioprocessing experts, Tom Fletcher, R&D Director at Irvine Scientific and Dr Don Traul, Product Specialist at TAP Biosystems, will present technical data on the use of the ambr 10 - 15ml micro bioreactor system, as a small scale perfusion culture mimic.

To access the webinar, scientists can register at: http://www.tapbiosystems.com/ambr_webinar/ambrIrvine_WebinarPR.htm.

During the webinar, Dr Traul will describe how the ambr system has been utilized as a semi-continuous chemostat model, present field data validating the scalability of the ambr system for continuous culture, and discuss associated DoE applications for media development.

Tom Fletcher will be presenting his use of the ambr system in an alternative semi-continuous mode and will describe the productivity benefits of using ambr to screen a range of candidate media formulations.

Dr Don Traul, TAP Biosystems’ ambr Product Specialist commented: "To date there has been a lack of good scale-down models of large-scale perfusion culture, which has prevented the widespread adoption of this technique as a method for increasing protein yields in biologics production.”

Traul added: “Perfusion culture is a good option for production of unstable or minimally expressing proteins or antibodies and I am pleased to be hosting a webinar alongside Tom Fletcher in which we’ll show proof-of-concept data for use of ambr as a scale down perfusion culture mimic. This will demonstrate how ambr may benefit scientists looking for a strategy to save valuable time with media and process development and will provide them with information on how to rapidly scale up an optimum perfusion culture process for improving production of difficult to manufacture biologics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck and TAP Biosystems Finalists for “Best Collaboration Award”
Recognizing ambr250 as a breakthrough technology for process development.
Wednesday, October 08, 2014
TAP and Gallus Co-host Free Webinar
Explaining the benefits of using ambr15 microbioreactors for DoE.
Wednesday, October 01, 2014
New Webinars Explore Feed Strategy Challenges Using Mini Bioreactors
Detailing how to achieve consistent feeding regimes for reproducible scale-up.
Thursday, September 25, 2014
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!